Satish Garg
Concepts (663)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hypoglycemic Agents | 100 | 2025 | 1208 | 17.760 |
Why?
| Diabetes Mellitus, Type 1 | 150 | 2025 | 3604 | 16.850 |
Why?
| Blood Glucose | 114 | 2025 | 2088 | 12.810 |
Why?
| Blood Glucose Self-Monitoring | 69 | 2024 | 596 | 12.110 |
Why?
| Insulin | 84 | 2024 | 2313 | 10.360 |
Why?
| Diabetes Mellitus, Type 2 | 57 | 2024 | 2421 | 9.100 |
Why?
| Diabetes Mellitus | 32 | 2024 | 991 | 8.140 |
Why?
| Hypoglycemia | 50 | 2023 | 427 | 6.970 |
Why?
| Insulin Infusion Systems | 38 | 2024 | 361 | 5.100 |
Why?
| Monitoring, Ambulatory | 17 | 2017 | 84 | 4.400 |
Why?
| Myometrium | 9 | 2021 | 35 | 4.310 |
Why?
| Buffaloes | 11 | 2021 | 12 | 4.270 |
Why?
| Diabetic Ketoacidosis | 12 | 2024 | 195 | 3.710 |
Why?
| Spermatozoa | 8 | 2024 | 91 | 3.640 |
Why?
| Periodicals as Topic | 7 | 2020 | 209 | 3.250 |
Why?
| Biosimilar Pharmaceuticals | 6 | 2020 | 25 | 3.180 |
Why?
| Hyperglycemia | 17 | 2022 | 321 | 3.170 |
Why?
| Insulin Glargine | 25 | 2022 | 79 | 3.120 |
Why?
| Glycosides | 10 | 2024 | 37 | 3.030 |
Why?
| Uterine Contraction | 8 | 2021 | 17 | 2.890 |
Why?
| Pregnancy in Diabetics | 13 | 2023 | 118 | 2.790 |
Why?
| Sperm Motility | 7 | 2024 | 30 | 2.670 |
Why?
| Dog Diseases | 4 | 2021 | 52 | 2.630 |
Why?
| Insulin Lispro | 14 | 2022 | 36 | 2.530 |
Why?
| Insulin Aspart | 9 | 2020 | 26 | 2.480 |
Why?
| Biomedical Technology | 5 | 2023 | 39 | 2.300 |
Why?
| Mercury | 4 | 2025 | 39 | 2.250 |
Why?
| Insulin, Long-Acting | 21 | 2022 | 61 | 2.210 |
Why?
| Overweight | 4 | 2025 | 524 | 2.180 |
Why?
| Pancreas, Artificial | 5 | 2024 | 70 | 2.150 |
Why?
| Humans | 208 | 2025 | 129078 | 2.130 |
Why?
| Cytokines | 7 | 2021 | 1997 | 2.110 |
Why?
| Calcium | 9 | 2024 | 1175 | 2.010 |
Why?
| Lead | 3 | 2024 | 55 | 1.830 |
Why?
| Sperm Capacitation | 6 | 2021 | 12 | 1.700 |
Why?
| Plant Extracts | 5 | 2019 | 179 | 1.680 |
Why?
| Telemedicine | 6 | 2021 | 773 | 1.660 |
Why?
| Antioxidants | 5 | 2020 | 559 | 1.570 |
Why?
| Female | 117 | 2025 | 68274 | 1.540 |
Why?
| Adult | 86 | 2025 | 35423 | 1.520 |
Why?
| Glucagon-Like Peptides | 4 | 2025 | 51 | 1.480 |
Why?
| Male | 101 | 2025 | 63248 | 1.470 |
Why?
| Sepsis | 3 | 2023 | 561 | 1.430 |
Why?
| Animals | 52 | 2025 | 34708 | 1.410 |
Why?
| Theileriasis | 2 | 2020 | 2 | 1.400 |
Why?
| Insulins | 2 | 2024 | 36 | 1.400 |
Why?
| Cattle | 9 | 2024 | 973 | 1.360 |
Why?
| Mite Infestations | 2 | 2020 | 6 | 1.340 |
Why?
| Injections, Subcutaneous | 11 | 2021 | 145 | 1.330 |
Why?
| Vasoconstriction | 2 | 2022 | 195 | 1.260 |
Why?
| rho-Associated Kinases | 3 | 2021 | 85 | 1.260 |
Why?
| Calcium Signaling | 3 | 2021 | 237 | 1.240 |
Why?
| Postprandial Period | 5 | 2020 | 103 | 1.220 |
Why?
| Obesity | 4 | 2025 | 2847 | 1.200 |
Why?
| Pre-Eclampsia | 10 | 2023 | 183 | 1.190 |
Why?
| Trace Elements | 2 | 2020 | 46 | 1.180 |
Why?
| Middle Aged | 54 | 2025 | 31024 | 1.170 |
Why?
| Diabetes Complications | 5 | 2020 | 227 | 1.140 |
Why?
| Drug Therapy, Combination | 14 | 2021 | 1020 | 1.120 |
Why?
| Non-alcoholic Fatty Liver Disease | 2 | 2021 | 255 | 1.120 |
Why?
| Trypanosomiasis | 2 | 2017 | 5 | 1.110 |
Why?
| 3-Hydroxybutyric Acid | 3 | 2024 | 15 | 1.110 |
Why?
| Insulin, Isophane | 6 | 2017 | 21 | 1.090 |
Why?
| Rats, Wistar | 11 | 2020 | 396 | 1.060 |
Why?
| Dermatitis, Atopic | 2 | 2021 | 335 | 1.050 |
Why?
| Pandemics | 5 | 2022 | 1516 | 1.050 |
Why?
| Drugs, Investigational | 2 | 2017 | 32 | 1.030 |
Why?
| Protein Kinase C | 2 | 2018 | 258 | 1.030 |
Why?
| Histamine | 2 | 2017 | 64 | 0.990 |
Why?
| Acrosome Reaction | 2 | 2024 | 3 | 0.970 |
Why?
| Pneumonia, Viral | 2 | 2020 | 361 | 0.940 |
Why?
| Coronavirus Infections | 2 | 2020 | 355 | 0.940 |
Why?
| Acrosome | 1 | 2024 | 5 | 0.930 |
Why?
| Dipeptidyl-Peptidase IV Inhibitors | 3 | 2013 | 45 | 0.920 |
Why?
| Uterus | 6 | 2021 | 204 | 0.900 |
Why?
| Monitoring, Physiologic | 6 | 2023 | 265 | 0.880 |
Why?
| Biomedical Research | 8 | 2017 | 654 | 0.880 |
Why?
| Treatment Outcome | 22 | 2025 | 10256 | 0.870 |
Why?
| Diabetic Nephropathies | 2 | 2025 | 274 | 0.860 |
Why?
| Weight Loss | 4 | 2025 | 724 | 0.850 |
Why?
| Angiotensin II | 1 | 2023 | 92 | 0.810 |
Why?
| Spleen | 3 | 2020 | 518 | 0.800 |
Why?
| Cross-Over Studies | 10 | 2020 | 517 | 0.800 |
Why?
| Dinoprost | 2 | 2021 | 30 | 0.790 |
Why?
| Receptor, Notch3 | 1 | 2022 | 3 | 0.790 |
Why?
| Glucagon-Like Peptide 1 | 3 | 2013 | 111 | 0.790 |
Why?
| Sulfones | 2 | 2020 | 107 | 0.780 |
Why?
| Benzamides | 2 | 2020 | 192 | 0.770 |
Why?
| Aorta | 2 | 2022 | 410 | 0.760 |
Why?
| Pregnancy | 23 | 2023 | 6256 | 0.750 |
Why?
| Nifedipine | 6 | 2021 | 28 | 0.740 |
Why?
| Glucose | 6 | 2024 | 976 | 0.740 |
Why?
| Intermediate Filament Proteins | 1 | 2021 | 57 | 0.740 |
Why?
| Signal Transduction | 6 | 2024 | 4867 | 0.740 |
Why?
| Administration, Inhalation | 4 | 2018 | 675 | 0.740 |
Why?
| Dose-Response Relationship, Drug | 14 | 2020 | 1974 | 0.730 |
Why?
| TRPC Cation Channels | 2 | 2021 | 12 | 0.730 |
Why?
| Arterial Pressure | 1 | 2022 | 118 | 0.730 |
Why?
| Type C Phospholipases | 2 | 2018 | 72 | 0.730 |
Why?
| Calcium Channel Blockers | 6 | 2021 | 125 | 0.730 |
Why?
| Dogs | 5 | 2021 | 372 | 0.730 |
Why?
| Reproducibility of Results | 13 | 2022 | 3047 | 0.720 |
Why?
| Insulin Antibodies | 2 | 2020 | 104 | 0.720 |
Why?
| Trypanosoma | 2 | 2017 | 7 | 0.720 |
Why?
| Mitochondrial Membranes | 1 | 2021 | 39 | 0.710 |
Why?
| Biopolymers | 1 | 2020 | 32 | 0.710 |
Why?
| Gelatin | 1 | 2020 | 40 | 0.710 |
Why?
| Endometritis | 2 | 2017 | 4 | 0.710 |
Why?
| Theileria annulata | 1 | 2020 | 1 | 0.700 |
Why?
| Chitosan | 1 | 2020 | 32 | 0.700 |
Why?
| Protein Precursors | 1 | 2021 | 126 | 0.700 |
Why?
| Copper Sulfate | 1 | 2020 | 7 | 0.700 |
Why?
| Exophthalmos | 1 | 2020 | 17 | 0.690 |
Why?
| Mutagens | 1 | 2020 | 17 | 0.690 |
Why?
| Cattle Diseases | 1 | 2020 | 20 | 0.690 |
Why?
| Diabetic Angiopathies | 6 | 2013 | 263 | 0.690 |
Why?
| Sodium-Glucose Transporter 1 | 2 | 2017 | 10 | 0.690 |
Why?
| Selenium | 1 | 2020 | 37 | 0.690 |
Why?
| Calcium Channels | 2 | 2018 | 149 | 0.680 |
Why?
| Betacoronavirus | 2 | 2020 | 266 | 0.680 |
Why?
| Sulfonylurea Compounds | 2 | 2018 | 47 | 0.680 |
Why?
| Patient Education as Topic | 6 | 2020 | 735 | 0.680 |
Why?
| Peste-des-petits-ruminants virus | 1 | 2019 | 1 | 0.670 |
Why?
| Polyalthia | 1 | 2019 | 1 | 0.670 |
Why?
| Oleic Acid | 1 | 2020 | 38 | 0.670 |
Why?
| Newcastle disease virus | 1 | 2019 | 17 | 0.670 |
Why?
| Infusions, Subcutaneous | 4 | 2016 | 20 | 0.670 |
Why?
| Mites | 1 | 2019 | 6 | 0.660 |
Why?
| Isoproterenol | 1 | 2020 | 111 | 0.660 |
Why?
| Peroxidase | 2 | 2017 | 183 | 0.650 |
Why?
| Aged | 25 | 2024 | 22068 | 0.650 |
Why?
| Down-Regulation | 1 | 2022 | 639 | 0.650 |
Why?
| Potassium Channels | 1 | 2020 | 139 | 0.640 |
Why?
| Young Adult | 24 | 2022 | 12310 | 0.640 |
Why?
| Endocannabinoids | 2 | 2019 | 40 | 0.630 |
Why?
| Toll-Like Receptors | 1 | 2020 | 182 | 0.630 |
Why?
| Oxidative Stress | 4 | 2020 | 1221 | 0.630 |
Why?
| Cardiovascular Diseases | 3 | 2025 | 2016 | 0.620 |
Why?
| Uterine Artery | 1 | 2019 | 74 | 0.620 |
Why?
| Mercuric Chloride | 1 | 2018 | 2 | 0.610 |
Why?
| Biosensing Techniques | 2 | 2018 | 115 | 0.600 |
Why?
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2018 | 18 | 0.600 |
Why?
| Wound Healing | 1 | 2020 | 310 | 0.590 |
Why?
| Voltage-Gated Sodium Channels | 1 | 2017 | 4 | 0.590 |
Why?
| Adolescent | 30 | 2022 | 20241 | 0.590 |
Why?
| Tocolysis | 1 | 2017 | 4 | 0.590 |
Why?
| Weight Gain | 6 | 2024 | 504 | 0.580 |
Why?
| Potassium Channels, Voltage-Gated | 1 | 2018 | 49 | 0.580 |
Why?
| Eucalyptus | 1 | 2017 | 7 | 0.580 |
Why?
| Ethanolamines | 1 | 2017 | 20 | 0.580 |
Why?
| KATP Channels | 1 | 2017 | 19 | 0.580 |
Why?
| Double-Blind Method | 9 | 2024 | 1864 | 0.580 |
Why?
| Vasodilation | 2 | 2019 | 480 | 0.570 |
Why?
| Oxytocin | 2 | 2016 | 48 | 0.570 |
Why?
| Hydrogen Sulfide | 1 | 2017 | 41 | 0.570 |
Why?
| Interleukins | 1 | 2019 | 245 | 0.570 |
Why?
| Immunoglobulin E | 1 | 2019 | 353 | 0.560 |
Why?
| Norepinephrine | 1 | 2018 | 218 | 0.560 |
Why?
| Self Care | 4 | 2013 | 369 | 0.560 |
Why?
| Mitochondria | 2 | 2021 | 840 | 0.560 |
Why?
| Hospitalization | 2 | 2024 | 2080 | 0.550 |
Why?
| Endothelium, Vascular | 3 | 2019 | 918 | 0.550 |
Why?
| Syringes | 3 | 2013 | 41 | 0.550 |
Why?
| NAV1.8 Voltage-Gated Sodium Channel | 1 | 2016 | 3 | 0.550 |
Why?
| Reactive Oxygen Species | 1 | 2020 | 578 | 0.550 |
Why?
| Coinfection | 1 | 2018 | 130 | 0.550 |
Why?
| Therapies, Investigational | 1 | 2017 | 14 | 0.550 |
Why?
| Cadmium | 1 | 2017 | 67 | 0.540 |
Why?
| Inflammation Mediators | 1 | 2020 | 503 | 0.540 |
Why?
| Minerals | 1 | 2016 | 39 | 0.530 |
Why?
| Muscle Relaxation | 1 | 2016 | 19 | 0.530 |
Why?
| Cholinesterases | 1 | 2016 | 8 | 0.530 |
Why?
| Diffusion of Innovation | 1 | 2017 | 95 | 0.520 |
Why?
| Calcium Channels, L-Type | 1 | 2017 | 114 | 0.510 |
Why?
| Ambulatory Care Facilities | 2 | 2023 | 226 | 0.510 |
Why?
| Receptors, Adrenergic, beta | 1 | 2016 | 126 | 0.500 |
Why?
| Body Mass Index | 8 | 2025 | 2250 | 0.500 |
Why?
| Myocytes, Cardiac | 1 | 2020 | 484 | 0.500 |
Why?
| Insulin, Regular, Human | 3 | 2024 | 42 | 0.500 |
Why?
| Vitamins | 1 | 2016 | 173 | 0.490 |
Why?
| Disposable Equipment | 2 | 2013 | 20 | 0.490 |
Why?
| Registries | 6 | 2024 | 1916 | 0.480 |
Why?
| Consensus | 7 | 2023 | 646 | 0.480 |
Why?
| Insulin Detemir | 5 | 2017 | 7 | 0.480 |
Why?
| Drug Delivery Systems | 2 | 2018 | 328 | 0.470 |
Why?
| Glucagon-Like Peptide-2 Receptor | 2 | 2025 | 14 | 0.470 |
Why?
| Gene Expression | 1 | 2020 | 1477 | 0.470 |
Why?
| Rats | 7 | 2020 | 5254 | 0.470 |
Why?
| Gastric Inhibitory Polypeptide | 2 | 2025 | 23 | 0.460 |
Why?
| Biomarkers | 12 | 2025 | 3878 | 0.460 |
Why?
| Drug Administration Schedule | 8 | 2017 | 760 | 0.450 |
Why?
| Withania | 1 | 2013 | 5 | 0.440 |
Why?
| Glucagon | 2 | 2022 | 105 | 0.440 |
Why?
| Antiviral Agents | 1 | 2019 | 708 | 0.430 |
Why?
| Receptors, Adrenergic, alpha-1 | 1 | 2013 | 44 | 0.430 |
Why?
| Extracellular Fluid | 1 | 2013 | 31 | 0.420 |
Why?
| Glucosides | 3 | 2019 | 37 | 0.420 |
Why?
| Retrospective Studies | 10 | 2025 | 14562 | 0.420 |
Why?
| Nervous System Diseases | 1 | 2016 | 260 | 0.420 |
Why?
| Chlorpyrifos | 1 | 2013 | 7 | 0.420 |
Why?
| United States | 16 | 2024 | 13992 | 0.420 |
Why?
| Benzhydryl Compounds | 3 | 2019 | 65 | 0.410 |
Why?
| History, 21st Century | 3 | 2020 | 183 | 0.410 |
Why?
| Membrane Potential, Mitochondrial | 3 | 2024 | 65 | 0.410 |
Why?
| Microsomes, Liver | 1 | 2013 | 64 | 0.410 |
Why?
| Portal Vein | 1 | 2013 | 106 | 0.400 |
Why?
| Time Factors | 12 | 2021 | 6579 | 0.400 |
Why?
| Myocardial Infarction | 1 | 2020 | 1031 | 0.400 |
Why?
| Pregnancy Outcome | 3 | 2023 | 379 | 0.390 |
Why?
| Ascorbic Acid | 1 | 2013 | 120 | 0.390 |
Why?
| Arsenic | 1 | 2013 | 65 | 0.390 |
Why?
| Pyrazines | 1 | 2013 | 88 | 0.390 |
Why?
| Tocolytic Agents | 2 | 2017 | 15 | 0.380 |
Why?
| Patient Preference | 1 | 2013 | 182 | 0.370 |
Why?
| Prevalence | 8 | 2020 | 2541 | 0.370 |
Why?
| Needles | 1 | 2011 | 57 | 0.370 |
Why?
| Triazoles | 1 | 2013 | 153 | 0.370 |
Why?
| Prospective Studies | 13 | 2024 | 7070 | 0.370 |
Why?
| Goats | 2 | 2021 | 25 | 0.360 |
Why?
| Clinical Trials as Topic | 7 | 2022 | 1005 | 0.360 |
Why?
| Adrenergic beta-Agonists | 2 | 2017 | 132 | 0.360 |
Why?
| History, 20th Century | 3 | 2019 | 295 | 0.350 |
Why?
| Blood Chemical Analysis | 2 | 2017 | 94 | 0.340 |
Why?
| DNA Damage | 2 | 2024 | 377 | 0.330 |
Why?
| Water Pollutants, Chemical | 1 | 2013 | 205 | 0.330 |
Why?
| Acetylcholine | 3 | 2019 | 185 | 0.330 |
Why?
| Nitric Oxide Synthase Type II | 2 | 2022 | 172 | 0.330 |
Why?
| Calibration | 3 | 2018 | 137 | 0.330 |
Why?
| China | 4 | 2020 | 187 | 0.320 |
Why?
| Pregnancy Trimester, First | 3 | 2020 | 133 | 0.320 |
Why?
| Organometallic Compounds | 2 | 2024 | 104 | 0.320 |
Why?
| 4-Aminopyridine | 2 | 2020 | 23 | 0.320 |
Why?
| Intention to Treat Analysis | 3 | 2017 | 72 | 0.320 |
Why?
| Health Care Costs | 4 | 2016 | 404 | 0.320 |
Why?
| Reference Values | 6 | 2023 | 791 | 0.310 |
Why?
| Plant Leaves | 3 | 2019 | 126 | 0.310 |
Why?
| Research Design | 6 | 2015 | 1039 | 0.310 |
Why?
| alpha-Tocopherol | 2 | 2020 | 32 | 0.300 |
Why?
| Prediabetic State | 1 | 2011 | 242 | 0.300 |
Why?
| Computer Systems | 2 | 2018 | 48 | 0.300 |
Why?
| Animals, Newborn | 2 | 2020 | 817 | 0.290 |
Why?
| Software | 3 | 2013 | 612 | 0.290 |
Why?
| Veratridine | 2 | 2017 | 6 | 0.290 |
Why?
| Blood Pressure | 4 | 2025 | 1746 | 0.280 |
Why?
| Anti-Bacterial Agents | 1 | 2017 | 1702 | 0.280 |
Why?
| Sodium-Glucose Transport Proteins | 2 | 2017 | 2 | 0.270 |
Why?
| Equipment Design | 4 | 2010 | 523 | 0.270 |
Why?
| Child | 11 | 2022 | 20860 | 0.270 |
Why?
| United States Food and Drug Administration | 3 | 2018 | 204 | 0.260 |
Why?
| Risk Factors | 8 | 2024 | 9804 | 0.260 |
Why?
| Nitric Oxide | 3 | 2022 | 892 | 0.260 |
Why?
| Vasodilator Agents | 2 | 2019 | 325 | 0.260 |
Why?
| Journal Impact Factor | 2 | 2020 | 31 | 0.260 |
Why?
| Ruthenium Red | 2 | 2016 | 8 | 0.250 |
Why?
| Diabetic Retinopathy | 2 | 2005 | 172 | 0.250 |
Why?
| Blotting, Western | 3 | 2017 | 1189 | 0.250 |
Why?
| Hypertension | 4 | 2011 | 1237 | 0.250 |
Why?
| Albuminuria | 3 | 2017 | 180 | 0.250 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2021 | 1204 | 0.250 |
Why?
| Tissue Culture Techniques | 2 | 2017 | 70 | 0.250 |
Why?
| Lipoproteins | 2 | 2019 | 170 | 0.240 |
Why?
| Copper | 2 | 2016 | 109 | 0.240 |
Why?
| Phenylephrine | 2 | 2016 | 75 | 0.240 |
Why?
| Exercise | 2 | 2014 | 1924 | 0.240 |
Why?
| Large-Conductance Calcium-Activated Potassium Channels | 2 | 2017 | 11 | 0.240 |
Why?
| Algorithms | 5 | 2018 | 1626 | 0.240 |
Why?
| Glomerular Filtration Rate | 3 | 2025 | 685 | 0.240 |
Why?
| Fasting | 1 | 2006 | 265 | 0.240 |
Why?
| Body Weight | 7 | 2020 | 936 | 0.240 |
Why?
| Semen Analysis | 1 | 2024 | 13 | 0.230 |
Why?
| Adrenergic beta-2 Receptor Agonists | 1 | 2004 | 34 | 0.230 |
Why?
| Phosphorylation | 2 | 2020 | 1686 | 0.230 |
Why?
| Calcinosis | 4 | 2010 | 255 | 0.220 |
Why?
| Pyrazoles | 2 | 2018 | 403 | 0.220 |
Why?
| Mass Screening | 1 | 2011 | 1129 | 0.220 |
Why?
| Cyclic AMP | 1 | 2024 | 230 | 0.220 |
Why?
| Uridine Diphosphate | 1 | 2023 | 3 | 0.210 |
Why?
| Drug Approval | 1 | 2024 | 88 | 0.210 |
Why?
| Dietary Supplements | 2 | 2018 | 533 | 0.210 |
Why?
| Equipment Failure | 2 | 2018 | 112 | 0.210 |
Why?
| Reproduction | 1 | 2025 | 200 | 0.210 |
Why?
| Aged, 80 and over | 3 | 2022 | 7063 | 0.200 |
Why?
| Endocrinology | 2 | 2016 | 74 | 0.200 |
Why?
| Receptors, Glucagon | 1 | 2022 | 27 | 0.200 |
Why?
| Vitamin D-Binding Protein | 2 | 2020 | 15 | 0.200 |
Why?
| Randomized Controlled Trials as Topic | 5 | 2021 | 1367 | 0.200 |
Why?
| Safety | 3 | 2009 | 330 | 0.200 |
Why?
| Mice | 5 | 2023 | 16583 | 0.190 |
Why?
| Ketosis | 1 | 2021 | 12 | 0.190 |
Why?
| Mobile Applications | 2 | 2021 | 158 | 0.190 |
Why?
| Reference Standards | 4 | 2017 | 169 | 0.190 |
Why?
| Testis | 2 | 2025 | 143 | 0.190 |
Why?
| Illinois | 1 | 2021 | 39 | 0.180 |
Why?
| Immunization, Passive | 1 | 2021 | 82 | 0.180 |
Why?
| Patient Isolation | 1 | 2021 | 16 | 0.180 |
Why?
| Los Angeles | 1 | 2021 | 62 | 0.180 |
Why?
| New York City | 1 | 2021 | 81 | 0.180 |
Why?
| Child, Preschool | 5 | 2022 | 10462 | 0.180 |
Why?
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2020 | 59 | 0.180 |
Why?
| Micronucleus Tests | 1 | 2020 | 5 | 0.170 |
Why?
| Patient Satisfaction | 3 | 2015 | 642 | 0.170 |
Why?
| Comet Assay | 1 | 2020 | 20 | 0.170 |
Why?
| Antigens, Viral | 1 | 2021 | 181 | 0.170 |
Why?
| Skin Diseases, Parasitic | 1 | 2020 | 2 | 0.170 |
Why?
| Environmental Exposure | 1 | 2025 | 479 | 0.170 |
Why?
| Progesterone | 2 | 2019 | 244 | 0.170 |
Why?
| Interleukin-13 | 1 | 2021 | 147 | 0.170 |
Why?
| Chromium | 1 | 2020 | 13 | 0.170 |
Why?
| Uncoupling Protein 2 | 1 | 2020 | 9 | 0.170 |
Why?
| Incidence | 3 | 2017 | 2635 | 0.170 |
Why?
| Disease Models, Animal | 2 | 2020 | 3999 | 0.170 |
Why?
| Practice Guidelines as Topic | 3 | 2019 | 1526 | 0.170 |
Why?
| Cardiotoxicity | 1 | 2020 | 33 | 0.170 |
Why?
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 1 | 0.170 |
Why?
| Curcumin | 1 | 2020 | 30 | 0.170 |
Why?
| Income | 1 | 2021 | 191 | 0.170 |
Why?
| Glycemic Index | 2 | 2009 | 25 | 0.170 |
Why?
| Transforming Growth Factor beta1 | 1 | 2020 | 162 | 0.170 |
Why?
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 9 | 0.170 |
Why?
| Cyclooxygenase 1 | 1 | 2019 | 25 | 0.170 |
Why?
| Vero Cells | 1 | 2019 | 70 | 0.160 |
Why?
| Virus Internalization | 1 | 2019 | 43 | 0.160 |
Why?
| Lipid Peroxidation | 1 | 2020 | 147 | 0.160 |
Why?
| Haptoglobins | 1 | 2019 | 51 | 0.160 |
Why?
| Host-Parasite Interactions | 1 | 2020 | 98 | 0.160 |
Why?
| Canagliflozin | 1 | 2019 | 9 | 0.160 |
Why?
| Area Under Curve | 3 | 2015 | 286 | 0.160 |
Why?
| Diabetes, Gestational | 1 | 2023 | 306 | 0.160 |
Why?
| Tyrosine | 1 | 2020 | 219 | 0.160 |
Why?
| Adamantane | 1 | 2019 | 16 | 0.160 |
Why?
| Liver Cirrhosis | 1 | 2021 | 274 | 0.160 |
Why?
| Immunity, Cellular | 2 | 2018 | 267 | 0.160 |
Why?
| Dipeptides | 1 | 2019 | 49 | 0.160 |
Why?
| Ion Channels | 1 | 2019 | 126 | 0.150 |
Why?
| TRPV Cation Channels | 1 | 2019 | 33 | 0.150 |
Why?
| California | 1 | 2020 | 402 | 0.150 |
Why?
| Congresses as Topic | 2 | 2020 | 217 | 0.150 |
Why?
| Vitamin D | 2 | 2020 | 384 | 0.150 |
Why?
| Meals | 1 | 2020 | 117 | 0.150 |
Why?
| Methyldopa | 1 | 2018 | 7 | 0.150 |
Why?
| Receptor, Cannabinoid, CB1 | 1 | 2018 | 40 | 0.150 |
Why?
| Patient Care Planning | 1 | 2019 | 152 | 0.150 |
Why?
| Organ Culture Techniques | 1 | 2018 | 145 | 0.150 |
Why?
| Sensitivity and Specificity | 4 | 2009 | 1842 | 0.150 |
Why?
| Aminooxyacetic Acid | 1 | 2017 | 1 | 0.150 |
Why?
| Self Efficacy | 1 | 2002 | 377 | 0.150 |
Why?
| Sodium Channel Agonists | 1 | 2017 | 1 | 0.150 |
Why?
| Receptors, Adrenergic, beta-3 | 1 | 2017 | 4 | 0.150 |
Why?
| Sodium Bicarbonate | 1 | 2018 | 40 | 0.150 |
Why?
| International Agencies | 1 | 2017 | 29 | 0.150 |
Why?
| Injections | 1 | 2018 | 174 | 0.150 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2020 | 529 | 0.150 |
Why?
| Hemoglobin A | 1 | 2017 | 22 | 0.150 |
Why?
| Serum Amyloid A Protein | 1 | 2017 | 31 | 0.150 |
Why?
| Malondialdehyde | 1 | 2017 | 28 | 0.150 |
Why?
| Administration, Oral | 2 | 2017 | 784 | 0.150 |
Why?
| Equivalence Trials as Topic | 1 | 2017 | 7 | 0.140 |
Why?
| Glyburide | 1 | 2017 | 35 | 0.140 |
Why?
| Analysis of Variance | 1 | 2020 | 1285 | 0.140 |
Why?
| Methanol | 1 | 2017 | 32 | 0.140 |
Why?
| Toll-Like Receptor 9 | 1 | 2017 | 31 | 0.140 |
Why?
| Alkynes | 1 | 2017 | 53 | 0.140 |
Why?
| Least-Squares Analysis | 1 | 2017 | 72 | 0.140 |
Why?
| Biomechanical Phenomena | 1 | 2021 | 784 | 0.140 |
Why?
| Protein Carbonylation | 1 | 2017 | 53 | 0.140 |
Why?
| Data Interpretation, Statistical | 1 | 2019 | 337 | 0.140 |
Why?
| HLA-DQ Antigens | 1 | 2018 | 180 | 0.140 |
Why?
| Adipokines | 1 | 2017 | 45 | 0.140 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 750 | 0.140 |
Why?
| Solvents | 1 | 2017 | 107 | 0.140 |
Why?
| Longitudinal Studies | 6 | 2020 | 2670 | 0.140 |
Why?
| Phytotherapy | 1 | 2017 | 76 | 0.140 |
Why?
| Patient Dropouts | 1 | 2017 | 65 | 0.140 |
Why?
| Patient Compliance | 2 | 2013 | 563 | 0.140 |
Why?
| Propanolamines | 1 | 2017 | 97 | 0.140 |
Why?
| Antibodies, Viral | 1 | 2021 | 599 | 0.140 |
Why?
| Islet Amyloid Polypeptide | 3 | 2013 | 48 | 0.140 |
Why?
| Immunization | 1 | 2019 | 416 | 0.140 |
Why?
| Clinical Protocols | 1 | 2018 | 256 | 0.140 |
Why?
| Cyclooxygenase 2 | 1 | 2017 | 172 | 0.140 |
Why?
| Anniversaries and Special Events | 1 | 2017 | 16 | 0.140 |
Why?
| Glycine | 1 | 2017 | 162 | 0.140 |
Why?
| Computer-Aided Design | 1 | 2017 | 41 | 0.140 |
Why?
| Fatty Acids, Nonesterified | 1 | 2017 | 158 | 0.140 |
Why?
| Furans | 1 | 2016 | 22 | 0.140 |
Why?
| Antigen Presentation | 1 | 2018 | 205 | 0.140 |
Why?
| Uric Acid | 1 | 2018 | 158 | 0.140 |
Why?
| Cell Survival | 1 | 2020 | 1085 | 0.130 |
Why?
| Indicators and Reagents | 1 | 2016 | 108 | 0.130 |
Why?
| Oleaceae | 1 | 2016 | 1 | 0.130 |
Why?
| Up-Regulation | 1 | 2020 | 850 | 0.130 |
Why?
| Piperidines | 1 | 2018 | 188 | 0.130 |
Why?
| Antibody Formation | 1 | 2018 | 284 | 0.130 |
Why?
| Combined Modality Therapy | 2 | 2017 | 1213 | 0.130 |
Why?
| In Vitro Techniques | 2 | 2016 | 1061 | 0.130 |
Why?
| Socioeconomic Factors | 1 | 2021 | 1192 | 0.130 |
Why?
| Antihypertensive Agents | 3 | 2012 | 487 | 0.130 |
Why?
| Coronary Artery Disease | 3 | 2010 | 695 | 0.130 |
Why?
| Sympathomimetics | 1 | 2016 | 26 | 0.130 |
Why?
| Pilot Projects | 2 | 2018 | 1548 | 0.130 |
Why?
| Cysteine | 1 | 2017 | 190 | 0.130 |
Why?
| Lung | 1 | 2009 | 3925 | 0.130 |
Why?
| Leptin | 2 | 2017 | 217 | 0.130 |
Why?
| Eating | 3 | 2009 | 366 | 0.130 |
Why?
| Anti-Inflammatory Agents | 1 | 2020 | 468 | 0.130 |
Why?
| Comorbidity | 1 | 2021 | 1542 | 0.130 |
Why?
| Membrane Potentials | 1 | 2016 | 261 | 0.130 |
Why?
| Amyloid | 2 | 2007 | 84 | 0.130 |
Why?
| Aniline Compounds | 1 | 2016 | 95 | 0.130 |
Why?
| Drug Hypersensitivity | 1 | 2017 | 92 | 0.130 |
Why?
| Estradiol | 1 | 2019 | 494 | 0.130 |
Why?
| Drug Design | 1 | 2017 | 156 | 0.130 |
Why?
| Forecasting | 2 | 2016 | 363 | 0.130 |
Why?
| Moringa oleifera | 1 | 2015 | 2 | 0.130 |
Why?
| Incretins | 1 | 2015 | 18 | 0.120 |
Why?
| Interleukin-10 | 1 | 2017 | 299 | 0.120 |
Why?
| Imidazoles | 1 | 2016 | 225 | 0.120 |
Why?
| RNA, Messenger | 1 | 2023 | 2702 | 0.120 |
Why?
| Postnatal Care | 1 | 2016 | 71 | 0.120 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 289 | 0.120 |
Why?
| Vascular Stiffness | 1 | 2021 | 479 | 0.120 |
Why?
| Toll-Like Receptor 4 | 1 | 2017 | 294 | 0.120 |
Why?
| Interleukin 1 Receptor Antagonist Protein | 2 | 2013 | 252 | 0.120 |
Why?
| Early Diagnosis | 2 | 2015 | 232 | 0.120 |
Why?
| Cells, Cultured | 2 | 2020 | 4063 | 0.120 |
Why?
| Disease Management | 1 | 2019 | 594 | 0.120 |
Why?
| Self-Management | 1 | 2017 | 159 | 0.120 |
Why?
| Materials Testing | 2 | 2017 | 344 | 0.110 |
Why?
| Estrenes | 1 | 2014 | 16 | 0.110 |
Why?
| Cholesterol, HDL | 1 | 2015 | 203 | 0.110 |
Why?
| Vitamin D Deficiency | 2 | 2020 | 179 | 0.110 |
Why?
| Case-Control Studies | 2 | 2019 | 3336 | 0.110 |
Why?
| Pyrrolidinones | 1 | 2014 | 28 | 0.110 |
Why?
| Inflammation | 1 | 2005 | 2696 | 0.110 |
Why?
| Gastrins | 1 | 2013 | 9 | 0.110 |
Why?
| Colesevelam Hydrochloride | 1 | 2013 | 8 | 0.110 |
Why?
| Kidney Diseases | 1 | 2017 | 366 | 0.110 |
Why?
| Allylamine | 1 | 2013 | 8 | 0.110 |
Why?
| Bromocriptine | 1 | 2013 | 27 | 0.110 |
Why?
| Sodium-Glucose Transporter 2 | 1 | 2013 | 21 | 0.110 |
Why?
| Colorado | 2 | 2020 | 4445 | 0.110 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2014 | 85 | 0.110 |
Why?
| Prenatal Care | 1 | 2016 | 272 | 0.110 |
Why?
| Staining and Labeling | 1 | 2014 | 142 | 0.110 |
Why?
| Escherichia coli | 1 | 2017 | 784 | 0.110 |
Why?
| Staphylococcus aureus | 1 | 2017 | 429 | 0.110 |
Why?
| Catecholamines | 1 | 2013 | 96 | 0.110 |
Why?
| Immunologic Factors | 1 | 2015 | 227 | 0.110 |
Why?
| Immunohistochemistry | 1 | 2017 | 1697 | 0.110 |
Why?
| Age Factors | 2 | 2019 | 3137 | 0.110 |
Why?
| Toxicity Tests, Subacute | 1 | 2013 | 1 | 0.110 |
Why?
| Chemistry, Pharmaceutical | 1 | 2013 | 104 | 0.110 |
Why?
| Enzyme Inhibitors | 1 | 2016 | 829 | 0.100 |
Why?
| Coronary Disease | 2 | 2007 | 389 | 0.100 |
Why?
| Cooperative Behavior | 1 | 2016 | 428 | 0.100 |
Why?
| Quality of Life | 5 | 2016 | 2711 | 0.100 |
Why?
| Circadian Rhythm | 4 | 2015 | 402 | 0.100 |
Why?
| Oxidation-Reduction | 1 | 2016 | 1014 | 0.100 |
Why?
| Sitagliptin Phosphate | 1 | 2013 | 32 | 0.100 |
Why?
| Leadership | 1 | 2017 | 356 | 0.100 |
Why?
| Autoantibodies | 2 | 2018 | 1464 | 0.100 |
Why?
| Menopause | 1 | 2016 | 301 | 0.100 |
Why?
| Patient Selection | 2 | 2009 | 671 | 0.100 |
Why?
| Thiazolidinediones | 1 | 2013 | 136 | 0.100 |
Why?
| Insecticides | 1 | 2013 | 34 | 0.100 |
Why?
| Delayed-Action Preparations | 1 | 2013 | 178 | 0.100 |
Why?
| Islets of Langerhans Transplantation | 1 | 2013 | 59 | 0.100 |
Why?
| T-Lymphocytes | 2 | 2018 | 1913 | 0.100 |
Why?
| Gene Expression Regulation | 2 | 2019 | 2523 | 0.100 |
Why?
| Zinc | 1 | 2015 | 291 | 0.100 |
Why?
| Cell Proliferation | 2 | 2016 | 2344 | 0.100 |
Why?
| Drinking Water | 1 | 2013 | 76 | 0.090 |
Why?
| Internet | 1 | 2016 | 616 | 0.090 |
Why?
| Self Administration | 1 | 2011 | 126 | 0.090 |
Why?
| Carotenoids | 1 | 2011 | 37 | 0.090 |
Why?
| Swine | 1 | 2013 | 740 | 0.090 |
Why?
| Managed Care Programs | 1 | 2011 | 135 | 0.090 |
Why?
| Cohort Studies | 4 | 2019 | 5400 | 0.090 |
Why?
| Regression Analysis | 2 | 2010 | 987 | 0.080 |
Why?
| Eicosapentaenoic Acid | 1 | 2010 | 35 | 0.080 |
Why?
| Home Care Services | 1 | 2013 | 246 | 0.080 |
Why?
| Surveys and Questionnaires | 4 | 2014 | 5365 | 0.080 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 339 | 0.080 |
Why?
| Metformin | 1 | 2013 | 307 | 0.080 |
Why?
| Drug Combinations | 1 | 2010 | 327 | 0.080 |
Why?
| Decision Making | 2 | 2013 | 837 | 0.080 |
Why?
| Carcinogens | 1 | 2009 | 111 | 0.080 |
Why?
| Physicians | 2 | 2017 | 848 | 0.080 |
Why?
| Vital Capacity | 1 | 2009 | 285 | 0.080 |
Why?
| Immunosuppressive Agents | 1 | 2013 | 699 | 0.080 |
Why?
| Disease Progression | 3 | 2012 | 2607 | 0.080 |
Why?
| Cross-Sectional Studies | 4 | 2015 | 5036 | 0.070 |
Why?
| Rats, Sprague-Dawley | 1 | 2013 | 2311 | 0.070 |
Why?
| Hepatitis A Virus Cellular Receptor 1 | 2 | 2018 | 44 | 0.070 |
Why?
| Forced Expiratory Volume | 1 | 2009 | 509 | 0.070 |
Why?
| Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| C-Reactive Protein | 2 | 2013 | 394 | 0.070 |
Why?
| Norway | 2 | 2019 | 42 | 0.070 |
Why?
| Drug Costs | 1 | 2008 | 110 | 0.070 |
Why?
| Sheep | 1 | 2010 | 832 | 0.070 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2007 | 72 | 0.070 |
Why?
| Infusion Pumps, Implantable | 2 | 2004 | 22 | 0.070 |
Why?
| Nebulizers and Vaporizers | 1 | 2007 | 82 | 0.070 |
Why?
| Australia | 2 | 2019 | 247 | 0.070 |
Why?
| Medication Adherence | 1 | 2011 | 569 | 0.070 |
Why?
| Renin-Angiotensin System | 1 | 2007 | 80 | 0.070 |
Why?
| Risk Management | 2 | 2019 | 92 | 0.070 |
Why?
| Societies, Medical | 1 | 2010 | 760 | 0.070 |
Why?
| Infant | 1 | 2020 | 8997 | 0.060 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 207 | 0.060 |
Why?
| Creatinine | 2 | 2018 | 486 | 0.060 |
Why?
| Attitude of Health Personnel | 1 | 2013 | 1090 | 0.060 |
Why?
| Patient Acceptance of Health Care | 1 | 2012 | 764 | 0.060 |
Why?
| Alprostadil | 1 | 2005 | 32 | 0.060 |
Why?
| Immunity, Humoral | 2 | 2016 | 118 | 0.060 |
Why?
| Spermatogenesis | 1 | 2025 | 62 | 0.060 |
Why?
| Barium Compounds | 1 | 2004 | 7 | 0.060 |
Why?
| Terbutaline | 1 | 2004 | 7 | 0.060 |
Why?
| Organ Size | 2 | 2016 | 446 | 0.060 |
Why?
| Potassium Chloride | 1 | 2004 | 34 | 0.060 |
Why?
| Abortifacient Agents, Nonsteroidal | 1 | 2004 | 21 | 0.060 |
Why?
| Receptors, Adrenergic, beta-2 | 1 | 2004 | 45 | 0.060 |
Why?
| Hyperlipidemias | 1 | 2005 | 124 | 0.060 |
Why?
| Dinoprostone | 1 | 2005 | 188 | 0.060 |
Why?
| Automation | 1 | 2004 | 81 | 0.060 |
Why?
| Albuterol | 1 | 2004 | 105 | 0.060 |
Why?
| Capillaries | 1 | 2004 | 98 | 0.060 |
Why?
| Pulmonary Artery | 1 | 2010 | 1095 | 0.050 |
Why?
| Homeostasis | 1 | 2007 | 605 | 0.050 |
Why?
| Chlorides | 1 | 2004 | 138 | 0.050 |
Why?
| Modems | 1 | 2003 | 1 | 0.050 |
Why?
| Glycation End Products, Advanced | 1 | 2023 | 62 | 0.050 |
Why?
| Fetal Macrosomia | 1 | 2003 | 60 | 0.050 |
Why?
| Transaminases | 1 | 2022 | 23 | 0.050 |
Why?
| Primary Health Care | 1 | 2013 | 1671 | 0.050 |
Why?
| Congenital Abnormalities | 1 | 2003 | 74 | 0.050 |
Why?
| Food | 1 | 2004 | 169 | 0.050 |
Why?
| Pregnant Women | 1 | 2023 | 118 | 0.050 |
Why?
| Costs and Cost Analysis | 1 | 2003 | 211 | 0.050 |
Why?
| Lipoproteins, LDL | 1 | 2022 | 131 | 0.050 |
Why?
| Educational Status | 1 | 2004 | 458 | 0.050 |
Why?
| Ketone Bodies | 1 | 2021 | 15 | 0.050 |
Why?
| Follow-Up Studies | 2 | 2020 | 4927 | 0.050 |
Why?
| Brain | 1 | 2013 | 2604 | 0.050 |
Why?
| Labor, Obstetric | 1 | 2002 | 55 | 0.050 |
Why?
| Preconception Care | 1 | 2002 | 39 | 0.050 |
Why?
| Age of Onset | 1 | 2003 | 494 | 0.050 |
Why?
| Prognosis | 2 | 2020 | 3793 | 0.050 |
Why?
| Ketones | 1 | 2021 | 47 | 0.050 |
Why?
| Breath Tests | 1 | 2021 | 91 | 0.050 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 421 | 0.040 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2021 | 91 | 0.040 |
Why?
| Pregnancy Trimester, Second | 1 | 2020 | 73 | 0.040 |
Why?
| Learning | 1 | 2004 | 384 | 0.040 |
Why?
| Self Concept | 1 | 2002 | 236 | 0.040 |
Why?
| Gestational Age | 1 | 2003 | 857 | 0.040 |
Why?
| Immunoglobulin Fc Fragments | 1 | 2020 | 39 | 0.040 |
Why?
| Birth Weight | 1 | 2003 | 494 | 0.040 |
Why?
| Skin | 1 | 2004 | 737 | 0.040 |
Why?
| Vascular Resistance | 1 | 2021 | 373 | 0.040 |
Why?
| Polyunsaturated Alkamides | 1 | 2019 | 7 | 0.040 |
Why?
| Capsaicin | 1 | 2019 | 25 | 0.040 |
Why?
| Arachidonic Acids | 1 | 2019 | 56 | 0.040 |
Why?
| Databases, Factual | 1 | 2004 | 1289 | 0.040 |
Why?
| Data Accuracy | 1 | 2019 | 59 | 0.040 |
Why?
| Postpartum Period | 1 | 2002 | 332 | 0.040 |
Why?
| Immunoblotting | 1 | 2019 | 302 | 0.040 |
Why?
| Sleep | 2 | 2015 | 657 | 0.040 |
Why?
| Internationality | 1 | 2019 | 149 | 0.040 |
Why?
| Microscopy, Polarization | 1 | 2018 | 31 | 0.040 |
Why?
| Sodium | 1 | 2019 | 205 | 0.040 |
Why?
| Osmolar Concentration | 1 | 2018 | 166 | 0.040 |
Why?
| Retinol-Binding Proteins, Plasma | 1 | 2017 | 6 | 0.040 |
Why?
| Resistin | 1 | 2017 | 10 | 0.040 |
Why?
| Multicenter Studies as Topic | 1 | 2019 | 288 | 0.040 |
Why?
| Lipocalin-2 | 1 | 2017 | 76 | 0.040 |
Why?
| Survival Rate | 1 | 2022 | 1886 | 0.040 |
Why?
| North America | 1 | 2018 | 289 | 0.040 |
Why?
| Fatty Acid-Binding Proteins | 1 | 2017 | 68 | 0.030 |
Why?
| Lost to Follow-Up | 1 | 2017 | 22 | 0.030 |
Why?
| Recombinant Fusion Proteins | 1 | 2020 | 642 | 0.030 |
Why?
| Seminiferous Tubules | 1 | 2016 | 12 | 0.030 |
Why?
| Semen | 1 | 2016 | 19 | 0.030 |
Why?
| Hypersensitivity, Delayed | 1 | 2016 | 28 | 0.030 |
Why?
| Hydrogen-Ion Concentration | 1 | 2018 | 542 | 0.030 |
Why?
| Drug Resistance | 1 | 2017 | 167 | 0.030 |
Why?
| Mice, Inbred NOD | 1 | 2018 | 579 | 0.030 |
Why?
| Models, Economic | 1 | 2016 | 56 | 0.030 |
Why?
| Cost Savings | 1 | 2016 | 83 | 0.030 |
Why?
| Research Personnel | 1 | 2017 | 161 | 0.030 |
Why?
| Kidney | 1 | 2023 | 1330 | 0.030 |
Why?
| Edema | 1 | 2016 | 127 | 0.030 |
Why?
| Drug Monitoring | 1 | 2017 | 193 | 0.030 |
Why?
| Polymorphism, Genetic | 2 | 2010 | 642 | 0.030 |
Why?
| Flowers | 1 | 2016 | 61 | 0.030 |
Why?
| Physician-Patient Relations | 1 | 2020 | 538 | 0.030 |
Why?
| Adiponectin | 1 | 2017 | 232 | 0.030 |
Why?
| Antibodies, Bacterial | 1 | 2016 | 138 | 0.030 |
Why?
| Equipment and Supplies | 1 | 2015 | 40 | 0.030 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2015 | 126 | 0.030 |
Why?
| Body Burden | 1 | 2015 | 7 | 0.030 |
Why?
| Interleukin-2 | 1 | 2016 | 428 | 0.030 |
Why?
| C-Peptide | 1 | 2015 | 163 | 0.030 |
Why?
| Neoplasms | 1 | 2009 | 2429 | 0.030 |
Why?
| Salmonella typhimurium | 1 | 2016 | 174 | 0.030 |
Why?
| Communication | 1 | 2020 | 839 | 0.030 |
Why?
| Academic Medical Centers | 1 | 2017 | 473 | 0.030 |
Why?
| Activities of Daily Living | 1 | 2017 | 382 | 0.030 |
Why?
| Genotype | 2 | 2010 | 1835 | 0.030 |
Why?
| Liver | 1 | 2022 | 1835 | 0.030 |
Why?
| Prenatal Diagnosis | 1 | 2015 | 189 | 0.030 |
Why?
| Delivery of Health Care | 1 | 2020 | 896 | 0.030 |
Why?
| Health Services Accessibility | 1 | 2020 | 894 | 0.030 |
Why?
| Data Display | 1 | 2013 | 20 | 0.030 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 822 | 0.030 |
Why?
| E-Selectin | 1 | 2013 | 53 | 0.030 |
Why?
| Electronic Health Records | 1 | 2020 | 971 | 0.030 |
Why?
| Cost-Benefit Analysis | 1 | 2016 | 616 | 0.030 |
Why?
| Chemokine CXCL10 | 1 | 2013 | 33 | 0.030 |
Why?
| Testosterone | 1 | 2016 | 382 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2018 | 2082 | 0.030 |
Why?
| Interleukin-6 | 1 | 2016 | 716 | 0.020 |
Why?
| Risk | 1 | 2015 | 867 | 0.020 |
Why?
| Statistics as Topic | 1 | 2013 | 306 | 0.020 |
Why?
| Bone and Bones | 1 | 2015 | 297 | 0.020 |
Why?
| Tetraethylammonium | 1 | 2011 | 17 | 0.020 |
Why?
| beta Carotene | 1 | 2011 | 21 | 0.020 |
Why?
| Vitamin A | 1 | 2011 | 56 | 0.020 |
Why?
| Phenotype | 1 | 2019 | 3062 | 0.020 |
Why?
| Receptors, Calcitriol | 1 | 2010 | 53 | 0.020 |
Why?
| Calcium Chloride | 1 | 2010 | 14 | 0.020 |
Why?
| Expert Testimony | 1 | 2010 | 37 | 0.020 |
Why?
| Serotonin Antagonists | 1 | 2010 | 31 | 0.020 |
Why?
| Cholesterol | 1 | 2012 | 400 | 0.020 |
Why?
| B-Lymphocytes | 1 | 2015 | 813 | 0.020 |
Why?
| Benzimidazoles | 1 | 2011 | 158 | 0.020 |
Why?
| Nitrites | 1 | 2010 | 81 | 0.020 |
Why?
| Intracellular Space | 1 | 2010 | 71 | 0.020 |
Why?
| Potassium | 1 | 2010 | 140 | 0.020 |
Why?
| Extracellular Space | 1 | 2010 | 124 | 0.020 |
Why?
| Vasoconstrictor Agents | 1 | 2010 | 130 | 0.020 |
Why?
| Nitric Oxide Synthase | 1 | 2010 | 238 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 957 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2017 | 2768 | 0.020 |
Why?
| Serotonin | 1 | 2010 | 321 | 0.020 |
Why?
| Angiotensins | 1 | 2007 | 10 | 0.020 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 22 | 0.020 |
Why?
| Long-Term Care | 1 | 2007 | 88 | 0.020 |
Why?
| Fatty Acids | 1 | 2010 | 415 | 0.020 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2007 | 53 | 0.020 |
Why?
| Insurance, Health, Reimbursement | 1 | 2007 | 95 | 0.020 |
Why?
| Peptides | 1 | 2011 | 904 | 0.020 |
Why?
| Models, Biological | 1 | 2013 | 1704 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2010 | 1968 | 0.020 |
Why?
| Fructosamine | 1 | 2005 | 15 | 0.020 |
Why?
| Hemoglobins | 1 | 2007 | 344 | 0.010 |
Why?
| Age Distribution | 1 | 2005 | 377 | 0.010 |
Why?
| Sex Distribution | 1 | 2005 | 358 | 0.010 |
Why?
| Tomography, X-Ray Computed | 2 | 2003 | 2530 | 0.010 |
Why?
| Hemoglobinuria | 1 | 2003 | 3 | 0.010 |
Why?
| Sex Characteristics | 1 | 2003 | 724 | 0.010 |
Why?
| Logistic Models | 1 | 2003 | 1966 | 0.010 |
Why?
| Insulin Resistance | 1 | 2003 | 1164 | 0.010 |
Why?
|
|
Garg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|